Patent Litigation Finance

Patent litigation finance (also called third-party litigation funding, litigation finance, or IP finance) is an arrangement in which an investment firm (the 'funder') pays the legal fees and costs of a patent infringement lawsuit in exchange for a percentage of any recovery (settlement or judgment). The patent holder retains ownership of the patents; the funder is not a party to the litigation; and if the case is lost, the funder loses its investment and the patent holder owes the funder nothing ('non-recourse financing'). The key economic exchange: the funder provides capital to cover legal fees, expert costs, and court costs (which for a case through trial can total $3–10M+ for a single U.S. patent case). In return, the funder receives a priority claim on the recovery — typically: (1) return of the funded capital as a first priority; (2) a multiple of the funded capital (e.g., 3× the amount funded), OR a percentage of gross recovery (typically 20–40%), whichever is greater. The patent holder receives the remaining recovery. Litigation finance enables inventors, small companies, universities, and operating companies with strong patent claims but limited resources to pursue infringement cases against deep-pocketed defendants — without paying hourly legal fees or risking their own balance sheet. The litigation finance industry has grown significantly since the mid-2000s. The global litigation finance market is estimated at $15–20+ billion in assets under management as of 2025, with patent cases representing a large portion of funded matters.

Litigation funders typically structure their return in one of two ways, and often take whichever is larger: (1) Percentage of gross recovery: the funder receives 20–40% of the total amount recovered (before attorney fees). The specific percentage depends on the perceived risk of the case, the funding amount relative to the expected recovery, and negotiating leverage. High-risk cases (uncertain validity, difficult infringement, complex damages) command higher percentages. Strong cases with clear infringement reads and large potential damages may attract funders willing to take 20–25%. (2) Multiple of invested capital: the funder receives 3–4× the total amount funded (e.g., if the funder invested $5M in legal fees, it receives $15–20M from the recovery before the patent holder sees any money). Capital multiples are common when the recovery is uncertain in timing — the multiple compensates for the time value of money and the risk of loss. Most sophisticated funding agreements have a hybrid waterfall: the funder first receives the return of its capital (return of investment), then its premium (either the multiple on top, or a percentage of gross that covers both the capital return and profit), and the patent holder receives the remainder. For portfolio deals (multiple cases funded together), the economics may be structured differently — the funder takes a percentage of aggregate portfolio recovery across all cases in the portfolio, which allows losing cases to be offset by winning ones from the funder's perspective while the patent holder benefits from single-portfolio terms.

Litigation funders evaluate patent cases through a rigorous underwriting process similar to commercial credit analysis or VC due diligence. Qualifying factors: (1) Patent quality: strong, issued U.S. patents (utility, design) with clear specifications, proper claim construction, and no obvious invalidity issues. Patents that survived IPR challenges or have been licensed on their merits are particularly attractive. (2) Clear infringement read: the claims must demonstrably read on at least one current, commercially significant product or process of the target defendant. Funders commission independent claim charts to verify this. (3) Damages potential: funders typically look for minimum realistic recovery of $10–20M, with many tier-1 funders requiring $50M+. The damages analysis must be supportable — either lost profits or a reasonable royalty on a defined revenue base. (4) Litigation team: preferably experienced patent litigation counsel with a trial track record. Funders may require the patent holder to engage specific firms or attorneys they trust. (5) No fatal defects: standing issues (proper assignment), statute of limitations (6-year damages bar), expired patents, clear license defenses, or IPR time bars all reduce fundability. (6) Favorable jurisdiction: cases in patent-friendly venues (D. Del., W.D. Tex.) are preferred. Cases with pending IPR petitions already filed reduce fundability significantly. Disqualifying factors: patents with prior art gaps obvious to funders' technical experts; patents with obvious § 101 eligibility issues in the art unit; targets without identifiable revenue or assets (uncollectable judgments); cases where the patent holder has already substantially compromised the case (adverse claim construction rulings, IPR institution).

Disclosure requirements for litigation finance vary by jurisdiction and are evolving. Current U.S. landscape: (1) Federal courts: there is no uniform federal rule requiring disclosure of litigation finance. However, many federal courts have adopted local rules or standing orders requiring parties to disclose the existence of litigation funding agreements and the identity of funders. Some courts require disclosure of funding terms. (2) Chief Justice Roberts' 2021 Year-End Report called for the Judicial Conference to develop uniform rules on litigation finance disclosure — ongoing. (3) Patent cases specifically: some districts with heavy patent dockets (D. Del., W.D. Tex.) have local rules or judges' standing orders requiring disclosure of litigation funders. In D. Del., disclosure of the funder's identity and its funding interest is generally required. (4) PTAB/IPR: the USPTO requires identification of all 'real parties in interest' in IPR petitions. A funder that has significant control over the litigation or a financial stake that could be considered a beneficial interest in the outcome may be a real party in interest — which could bar the IPR if the funder was in privity with a party that is time-barred from filing. Courts have been split on when funders constitute real parties in interest. (5) International arbitration: major arbitration institutions (ICC, LCIA, SIAC, HKIAC) have adopted rules requiring disclosure of litigation funding arrangements. Strategy: patent holders and counsel should proactively identify disclosure requirements in the specific forum before finalizing funding arrangements — and negotiate funding agreement terms with potential disclosure in mind.

Litigation finance carries several risks for patent holders beyond the obvious one (sharing recovery): (1) Loss of settlement control: if the funding agreement gives the funder veto rights over settlements above a certain threshold, the patent holder may be pressured to reject settlements they would otherwise accept — particularly if the case is going well and a settlement would return the funder's capital but not its expected multiple. Well-negotiated agreements preserve the patent holder's ultimate settlement authority. (2) Privilege risk: sharing privileged legal analysis with the funder during due diligence may waive privilege, allowing the defendant to obtain those communications in discovery. Use a common-interest agreement before sharing any privileged materials. (3) Strategic misalignment: funders are financial investors who may not value non-monetary settlement terms (licenses, cross-licenses, business relationships) that the patent holder values. A settlement structured as a license with ongoing royalties may be worth more to the patent holder than a lump-sum payment — but the funder may prefer the lump sum for liquidity. (4) Disclosure risk: in jurisdictions requiring disclosure, the existence and terms of funding may be disclosed to the defendant — potentially affecting settlement dynamics or revealing information about the patent holder's financial position. (5) Loss of flexibility: once funded, the patent holder has reduced flexibility to settle cheap, reduce claims, or exit the case on terms that don't satisfy the funder's return. (6) Reputation: some defendants and courts view funded cases skeptically, and funding status can affect litigation dynamics at the margin. Overall, litigation finance is overwhelmingly beneficial to underfunded patent holders with meritorious cases — these risks are manageable with proper agreement drafting and counsel.